Distinguishing Type 2 Diabetes from Type 1 Diabetes in African American and Hispanic American Pediatric Patients by Keller, Nancy et al.
Distinguishing Type 2 Diabetes from Type 1 Diabetes in
African American and Hispanic American Pediatric
Patients
Nancy Keller
1*, Suruchi Bhatia
2, Jeanah N. Braden
1, Ginny Gildengorin
1, Jameel Johnson
3, Rachel
Yedlin
1, Teresa Tseng
4, Jacquelyn Knapp
1, Nicole Glaser
5, Paula Jossan
1, Shawn Teran
1, Erinn T.
Rhodes
6, Janelle A. Noble
1
1Children’s Hospital and Research Center Oakland, Oakland, California, United States of America, 2Division of Endocrinology and Diabetes, Sutter Pacific Medical Center,
San Francisco, California, United States of America, 3Michael E. Debakey Veterans Affairs Medical Center, Houston, Texas, United States of America, 4Children’s Medical
Center, University of Texas Southwestern, Dallas, Texas, United States of America, 5Department of Pediatrics, Pediatric Endocrinology, UC Davis Medical Center,
Sacramento, California, United States of America, 6Division of Endocrinology, Children’s Hospital Boston, Boston, Massachusetts, United States of America
Abstract
Objective: To test the hypothesis that clinical observations made at patient presentation can distinguish type 2 diabetes
(T2D) from type 1 diabetes (T1D) in pediatric patients aged 2 to 18.
Subjects and Methods: Medical records of 227 African American and 112 Hispanic American pediatric patients diagnosed as
T1D or T2D were examined to compare parameters in the two diseases. Age at presentation, BMI z-score, and gender were
the variables used in logistic regression analysis to create models for T2D prediction.
Results: The regression-based model created from African American data had a sensitivity of 92% and a specificity of 89%;
testing of a replication cohort showed 91% sensitivity and 93% specificity. A model based on the Hispanic American data
showed 92% sensitivity and 90% specificity. Similarities between African American and Hispanic American patients
include: (1) age at onset for both T1D and T2D decreased from the 1980s to the 2000s; (2) risk of T2D increased markedly
with obesity. Racial/ethnic-specific observations included: (1) in African American patients, the proportion of females was
significantly higher than that of males for T2D compared to T1D (p,0.0001); (2) in Hispanic Americans, the level of glycated
hemoglobin (HbA1c) was significantly higher in T1D than in T2D (p,0.002) at presentation; (3) the strongest contributor to
T2D risk was female gender in African Americans, while the strongest contributor to T2D risk was BMI z-score in Hispanic
Americans.
Conclusions: Distinction of T2D from T1D at patient presentation was possible with good sensitivity and specificity using
only three easily-assessed variables: age, gender, and BMI z-score. In African American pediatric diabetes patients, gender
was the strongest predictor of T2D, while in Hispanic patients, BMI z-score was the strongest predictor. This suggests that
race/ethnic specific models may be useful to optimize distinction of T1D from T2D at presentation.
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Introduction
Pediatric type 1 diabetes (T1D) and type 2 diabetes (T2D)
patients have become more similar to each other than they were
25 years ago. T1D patients are increasingly apt to be overweight/
obese, and the age of T2D diagnosis is decreasing to the point that
a patient as young as eight years old may no longer simply be
assumed to have T1D, rather than T2D [1,2,3,4,5]. The rising
incidence of T2D is particularly striking in the African American
(AA) and Hispanic American (HA) pediatric populations, who are
particularly at risk for T2D due to genetic and environmental
influences [6,7,8]. African American and Hispanic American
children from low income families are at high risk for T2D and are
often underinsured or have no medical insurance with limited
access to medical treatment [9,10].
In this study, data from African American and Hispanic
American pediatric diabetes patients were obtained retrospectively
to examine differences between T1D and T2D patients at onset
and to determine whether or not those differences could be utilized
to create a simple, rapid, and inexpensive test to aid in the
diagnosis of diabetes type in these populations. Such a test would
help with appropriate allocation of scarce resources, such as
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with and lead to prompt initiation of medical management with
appropriate family education and care plans.
The study reported here was made to determine: (1) whether or
not clinical observational data recorded at presentation could be
used to predict T2D and (2) whether or not measurable and
significant racial/ethnic differences in clinical observations might
necessitate race/ethnic specific diagnostic aids to differentiate
between T1D and T2D at presentation.
Methods
Ethics Statement
The study involved chart review, did not include any direct
patient involvement, and the data was analyzed anonymously. The
study was performed with the approval of the IRBs of the three
participating institutions: University of California, Davis Medical
Center, Sacramento, California, USA; Children’s Hospital Boston,
Boston, Massachusetts, USA; Children’s Hospital & Research
Center Oakland, Oakland, California, USA.
Subjects and data
Clinical observations of African American and Hispanic
American males and females made at presentation (first visit after
determination of hyperglycemia) were obtained from medical
records. From 285 charts of African American patients, 58 patients
were excluded due to missing data from presentation (n=50) or
unclear diagnosis (n=8). Data were abstracted from the remaining
227 medical records; 224 of these patients were between the ages
of 2 and 18 and were used in the model (Table 1). From 168 charts
of Hispanic American patients, 56 patients were excluded due to
missing data from presentation (n=21), unclear diagnosis (n=28),
and diagnosis of diabetes other than T1D or T2D (n=7). Data
were abstracted from the remaining 112 medical records; 105 of
these patients, between the ages of 2 and 18, were used for the
model (Table 1). Data from children younger than 2 years of age
were not used in any analysis that included BMI z-score because
BMI measurement in children under 2 may be inaccurate.
Presentation dates in the data set spanned two decades, beginning
in the 1980s.
The patients were seen at three medical centers: Children’s
Hospital and Research Center Oakland, Oakland, California,
USA; UC Davis Medical Center, Sacramento, California, USA
and Children’s Hospital Boston, Boston, Massachusetts, USA. The
study involved chart review and did not include any direct patient
involvement. The study was performed with the approval of the
Institutional Review Boards of the three participating institutions.
Racial/ethnic status was abstracted from chart data and
confirmed by clinician interview.
Data from patients with questionable race/ethnicity, borderline
diabetes (e.g., impaired glucose tolerance), diabetes secondary to
another condition or treatment (e.g., anti-inflammatory steroid
treatment), or known diagnosis of maturity onset diabetes in youth
(MODY) were excluded. Because these data were collected
retrospectively, with some records many years old, the date of
diagnosis and the record of height and weight did not always
coincide exactly. Records were used for the study only when
height and weight measurements were recorded within one month
of presentation. Results of HbA1c analysis were only used if the
measurement was made within one month of presentation. Family
history of diabetes and presence of acanthosis nigricans (an
indicator of high blood insulin levels in type 2 diabetes patients)
Table 1. Characteristics of Patients in the Age Range of 2–18 years.
African American Hispanic American
T1D N T2D N T1D N T2D N
Number of patients 124 100 69 39
Gender
% female 43% 72%* 51% 41%
BMI z-score
{ mean (6sd)
females 20.13 (2.12) 53 2.11 (0.70) 72 0.36 (1.80) 35 2.34 (0.34) 16
males 0.03 (2.50) 71 2.43 (0.47) 28 0.43 (1.28) 34 2.31 (0.35) 23
% z-score $2
{
males plus females 16 79 12 87
Age at presentation** mean (6 sd)
females 7.4 (3.8) 53 13.3
N (2.5) 72 8.8 (3.6) 35 11.7 (2.4) 16
males 9.4 (4.1) 71 14.4 (1.8) 28 8.1 (3.8) 34 13.7 (1.7) 23
C-peptide
1 (nmol/L)
mean (6 sd) 0.47 (0.33) 22 3.18 (2.08) 43 1.08 (1.76) 17 3.51 (2.04) 14
high C-peptide 6% 16 93% 30 9% 11 100% 4
GAD65 antibodies
% positive 61% 59 0% 47 56% 55 13% 32
*proportion of females in T2D vs.T1D, p,0.0001.
{mean BMI z-score higher in T2D than in T1D in both genders and in both ethnicities, p,0.0004 for all comparisons tested.
{% of patients of both genders.
**males significantly older than females in African American T1D (p=0.012), African American T2D (p=0.037), Hispanic American T2D (p=0.0091).
NAfrican American T2D females older than Hispanic American T2D females, p,0.03.
1For C-peptide, normal is less than 1.36 nmol/L.
doi:10.1371/journal.pone.0032773.t001
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regression analyses, but data were too sparse to allow their
inclusion. Patients younger than two years of age at presentation
were excluded from analyses involving BMI z-score.
Established, physician-confirmed diabetes diagnoses were those
recorded after at least one year of treatment. The physician used
his or her clinical judgment, paired with either direct knowledge of
the patient and clinical laboratory data, or thorough examination
of both the recorded observational data and the clinical laboratory
data to establish the diagnosis. Observational data used in
diagnosis included gender, age, height, weight, family history,
polyuria, and polydipsia. Clinical laboratory data included some
combination of: levels of autoantibodies known to be associated
with beta cell destruction (ICA, IAA, GAD65, and IA-2), blood
glucose, C-peptide, glycated hemoglobin (HbA1c), blood pH, and
diabetes medication. At the time of data abstraction, African
American patients in the study had been treated for a mean of 4.9
years (range 1 to 18 years), and Hispanic American patients had
been treated for a mean of 3.7 years (range 1 to 10 years). The
respective median treatment periods were 4 and 3.5 years. Data
from both genders were combined: (1) for determination by race/
ethnicity of T2D and T1D rates of decline in age at presentation
over the last two decades; (2) for determination by race/ethnicity
of mean glycated hemoglobin values in T1D and T2D patients at
presentation; and (3) for determination of changes in BMI z-score
vs. patient age at presentation.
The logistic regression analysis of three variables – age at
presentation, BMI z-score at presentation, and gender – were used
to determine sensitivity (correct prediction of T2D), specificity
(correct prediction of T1D), and the odds ratios of each variable
for risk of T2D.
Statistical Analysis
Graphical representations, statistical significance of differences
between data groups, and bivariate linear regression analyses were
generated with GraphPad Prism 5 (GraphPad Software, Inc., La
Jolla, CA, USA). Pearson’s chi-square test with one degree of
freedom was used to test for a statistically significant difference in
the subgroup distribution of females and males in each type of
diabetes. Group means were compared for statistically significant
differences by an unpaired t-test with Welch’s correction, applied
when equal variances cannot be assumed. Statistical differences
between slopes of bivariate linear regression lines were determined
by an F test.
Multivariate logistic regression analysis was performed with
SAS version 9.2 (Cary, North Carolina, USA). From the pool of
224 African American patients, aged 2–18, 150 were randomly
selected for the initial analysis. The remaining 74 African
American patients served as a replication cohort. From the
Hispanic American patient data set, 105 patients, aged 2–18, were
submitted for multivariate logistic regression analysis. The
statistician was blinded to the patients’ diagnoses by physicians
until after the computations were complete.
Area under the receiver operating characteristic curves (AUC of
ROC curves) was calculated in GraphPad Prism 5 by entering 1)
percent sensitivity and 2) 100% minus percent specificity directly
into the GraphPad Prism 5 table. The GraphPad program was
used only to calculate AUC, not to compute sensitivity and
specificity; those values were taken directly from SAS multivariate
logistic regression analysis. For each probability computed by SAS,
the associated percent specificity was subtracted from 100% to
calculate the false positives values. These were entered into
GraphPad to create the ROC graph and compute the AUC.
Results
Gender distribution
Gender distribution differed significantly (p,0.0001) between
the African American T2D patients (72% female) and the African
American T1D patients (43% female). However, no significant
difference was observed between T2D and T1D gender
distribution in the Hispanic American patients (p=0.42) (Table 1).
BMI z-score
BMI is a gender-specific measure of body mass index (BMI) that
is normalized for age. The BMI z-score for a given BMI is the
number of standard deviations away from the BMI norm for
gender and age. For T1D, BMI z-scores were highly variable in
both African American and Hispanic American patients, as shown
by the large standard deviations of the group means (Table 1).
T2D BMI z-scores were not only much higher than T1D scores
but also less variable.
Figure 1. Linear regression of BMI z-score vs. age at presentation. Age range at presentation, age 2–18. The T1D BMI z-score tended to
increase as the age at presentation increased from 2 to 18 years. In African American patients the rate of increase was not significant, however the
rate of the increase in T1D BMI z-score of Hispanic American patients was small but significant (p=0.008). In T2D patients, the trend of BMI z-score
was down as the age of presentation went up. The rate of decrease in African American patients was small but significant (p=0.01); in Hispanic
American patients the rate of decrease was insignificant. (N) T1D, (o) T2D.
doi:10.1371/journal.pone.0032773.g001
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addition, a significant percentage of T1D patients were obese
(BMI z-score $2) at this time. The percentage of obese T1D
African American patients was 16% and in Hispanic American
patients was 12% (Table 1).
BMI z-scores increased slightly but steadily with an increase in
the age at presentation in T1D patients and decreased slightly but
steadily in T2D patients (Figure 1). Thus, the T2D scores tended
to slightly diminish toward the norm, but were still very high over
the onset age range of 2–18 years.
Age at presentation
Mean age at onset was lower for females than for males
(p,0.04), with the exception of T1D Hispanic American females
whose mean age was older than that of T1D males (Table 1).
The decline in age at presentation for T1D and T2D has been
shown in other studies [1,11]. The study reported here
demonstrates similar decreases in age at presentation (Figure 2).
The decreases in age at presentation illustrate a confounding
factor in the differential diagnosis of T2D and T1D and pose a
challenge to developing a diagnostic aid for use at presentation.
The overlapping of age at presentation between T1D and T2D
patients is illustrated graphically in Figure 3. The overlap was
particularly pronounced in the age range of 10 to 15 years.
Combining the data from both minority groups, most of the
younger T2D patients were females. Of the 51 male T2D patients
in the study only one presented younger than 10 years of age. In
contrast, 14% of T2D females (12 out of a total of 88 AA and HA
females) were under 10 years of age at presentation. This
difference was statistically significant (p=0.031).
Glycated hemoglobin (HbA1c) at onset of diabetes
The HbA1c data recorded within one month of presentation
were available for a subset of 97 African American patients and a
subset of 95 Hispanic American patients. No gender differences
were observed in HbA1c for either AA or HA patients (data not
shown). The mean HbA1c in T2D Hispanic American patients
was significantly less than that in T1D (p,0.002) (Table 2). Mean
glycated hemoglobin in African American patients was similar in
T2D and T1D.
Multivariate logistic regression and prediction of T2D
In the abstracted data, several variables differed significantly
between T1D and T2D patients, including BMI, gender, C-
peptide, anti-GAD autoantibodies, current use of oral diabetes
medications, hyperpigmentation, and family history for T2D (data
not shown). Of the subset of variables that can be assessed
Figure 2. Linear regression of age at presentation vs. year of birth. Age range at presentation, age 1–18. African American T1D
regression line slope was 20.56 (r
2=0.46); T2D slope was 20.37 (r
2=0.32). Hispanic American T1D regression line slope was 20.76 (r
2=0.66); T2D
slope was 20.57 (r
2=0.44). The African American T1D and T2D rates of decrease in age were significantly different (p=0.04). The Hispanic American
T1D and T2D rates of age decrease were not significantly different. (N) T1D, (o) T2D.
doi:10.1371/journal.pone.0032773.g002
Figure 3. Number of patients per age at presentation. Age at presentation of T2D began to overlap age at presentation of T2D at age 8 or 9.
(N) T1D, (o) T2D.
doi:10.1371/journal.pone.0032773.g003
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BMI z-score had sufficient data available for use in constructing a
predictive model. One hundred fifty of 224 eligible African
American patient records were randomly selected for inclusion in
the analysis constructing the model. Using a cut point of 0.5,
results of regression analysis gave a sensitivity of 92% (correct
prediction of T2D) and specificity (correct prediction of T1D) of
89%. Application of the model from this logistic regression analysis
to the remaining 74 African American patient records validated
the results: sensitivity was 91% and the specificity was 93%.
Application of the model generated from African American data
to a cohort of 89 Hispanic American patients produced lower
sensitivity and specificity values: 79% and 87%, respectively. The
Hispanic American data set was then expanded until the number
of eligible patients reached 105. With 105 Hispanic American
patients, logistic regression produced a model with sensitivity and
specificity of 92% and 90%, respectively. The progress of the
model development is summarized in Table 3.
The odds ratios obtained illustrated the importance of female
gender as a risk factor for T2D in African Americans and showed
that BMI was prominent as a risk factor for both African
American and Hispanic Americans. Increasing age at presentation
increased the odds of T2D in both African American and Hispanic
American patients (Table 4).
ROC (receiver operating characteristic) curves
The ROC curve is a measure of the utility of the test for
prediction of T2D. A ROC area under the curve (AUC) ranges
from 0.5 (no predictive value) to 1.0 (perfect predictive value). The
AUC of 0.855 (95% CI 0.814–0.896) in the African American
patient group indicates that this test for T2D is very useful in
differentiating between T2D and T1D. The Hispanic American
patient group data yielded a similarly good result: AUC of 0.858
(95% CI 0.808–0.908). The ROC curves are shown in Figure 4.
Discussion
Thirty years ago, T2D was rare in children. Generally, children
presenting with elevated blood glucose were considered T1D
patients and adults presenting with elevated blood glucose were
considered T2D patients. In the interim, previously unrecognized
forms of diabetes, including MODY (maturity onset of diabetes in
youth) and LADA (latent autoimmune diabetes in adults), have
blurred the differential diagnosis of diabetes to some extent. The
biggest contributor to difficulty in the differential diagnosis of T1D
vs. T2D, however, is decreasing age of onset for both T1D and
T2D, but particularly for T2D. As a consequence of the
decreasing age at presentation over the last two decades, the age
at presentation of T2D overlapped that of T1D in both African
American and Hispanic American patients. Decreasing age of
T1D onset in our data is similar to that of several long-term studies
in England, Finland, and Italy [12,13,14]. A dramatic decrease in
the age of onset for T2D has been noted in several studies and is
particularly striking in non-Caucasian groups, such as African
Americans, Hispanics, and Native Americans, who are, for reasons
not yet fully understood, particularly susceptible to T2D
[15,16,17]. This makes distinction of T1D vs. T2D particularly
challenging in these groups and is the basis for the current study.
Overweight/obesity was a strong predictor of T2D in both
African American and Hispanic American youth; however, the
odds ratio for BMI z-score was far greater in HA (25.6) than in AA
(4.1). Many lines of evidence support the notion that race/
ethnicity can be an important factor in T2D susceptibility.
Prevalence of obesity varies among ethnic groups. In a recent
study, prevalence of obesity among 4 year old U.S. children was
reported as: 31% in American Indian/Native Alaskan, 22% in
Hispanic American, 21% in African American, 16% in European
American, and 13% in Asian American [18]. Among youth with
T2D, Asians had a lower mean BMI than did Pacific Islanders,
33.7 vs. 42.4, suggesting that Asian youth may be at risk for T2D
at a lower BMI than other racial/ethnic groups [19]. Similarly, a
study of adults found that South Asian T2D patients had lower
BMI than did European white T2D patients [20]. Thus, although
BMI is strongly correlated with T2D, other factors, perhaps
genetic or cultural, combine with BMI to determine susceptibility.
Our data show that the predictive test we are developing performs
much better when used for patients who belong to the group with
which it was created, i.e., the predictive value for HA patients is
better when the HA-specific model is used, rather than the AA-
specific model. Taken together, all of these observations
underscore the fact that race/ethnicity plays a role in T2D
susceptibility and should be taken into account when attempting to
distinguish diabetes type.
The uneven gender distribution in African American T2D
reported here, with significantly more females than males, is
consistent with other studies [2,7]. The absence of this gender bias
in Hispanic American patients is also consistent with previous
Table 2. Glycated hemoglobin at onset of diabetes.
T1D HbA1c N T2D HbA1c N p-value*
African American
mean (6 sem) 10.78 (60.31) 52 10.96 (60.45) 45 0.74
Hispanic American
mean (6 sem) 11.34 (60.31) 59 9.41 (60.44) 36 ,0.002
*mean T1D vs. mean T2D.
doi:10.1371/journal.pone.0032773.t002
Table 3. Logistic Regression Model Development in African
American (AA) and Hispanic American (HA) Patient Groups.
Model (M) Tested on: No. patients Sensitivity Specificity
M-AA created ---- 150 92 89
M-AA test* AA 74 91 93
M-AA test** HA 89 79 87
M-HA created ---- 105 92 90
*The model created with AA data was tested in a separate cohort of AA
patients.
**The model created with AA data was tested in HA patients.
doi:10.1371/journal.pone.0032773.t003
Table 4. T2D Odd Ratios (95% confidence limits).
African American Hispanic American
Variable Odds Ratio (95%CL) Odds Ratio (95%CL)
Female gender 12.95 (3.54 to 47.4) 0.74 (0.19 to 3.02)
BMI z-score 4.10 (2.19 to 7.68) 25.6 (4.85 to 135.0)
Age at presentation 1.97 (1.52 to 2.53) 1.49 (1.16 to 1.93)
doi:10.1371/journal.pone.0032773.t004
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and T2D in African American but not in Hispanic American
patients, the lesser prominence of BMI in risk of T2D in African
American patients, and the difference in T1D and T2D glycated
hemoglobin in Hispanic American patients at onset may all reflect
differences in underlying genetic influences in the two populations
in this study.
Other research supports the notion of race-specific genetic
differences that could affect T2D risk. Examination of healthy
pediatric subjects showed higher insulin secretion and lower
insulin clearance in African American subjects compared to
European American subjects [21,22]. The metabolic syndrome,
which can precede type 2 diabetes, has different characteristics in
European Americans, African Americans, and Hispanic Ameri-
cans [23]. Fatty acid metabolism is different in African Americans
compared to European Americans due to a genetic difference in a
key enzyme [24].
This study demonstrates that only a few variables recorded at
presentation may provide a model that could aid in differential
diagnosis of T1D and T2D in African American and Hispanic
American pediatric patients at the time of presentation. This study
also provides evidence that models to predict T2D from data
recorded at presentation should be race/ethnicity specific because
the relative risk of T2D as indicated by gender and BMI z-score is
different in African American and Hispanic American patients.
These results suggest that other racial/ethnic groups may have
their own levels of risk for T2D due to age, gender, and BMI z-
score.
A larger study, with data collected prospectively, is currently in
the planning stage. Data from this survey-type study will be
utilized to replicate the present work, improve the accuracy of
prediction of T2D, and test whether the addition of more
observational variables, such as presence or absence of acanthosis
nigricans, can further improve the prediction of diabetes type. The
data presented here suggest that an immediate, simple, rapid, and
inexpensive test can be developed to predict diabetes type at
presentation in underserved minority children and youth.
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